



Judy Rummel

Chair, Fed Up! Coalition
Steering Committee
President,
Steve Rummel Hope Foundation

Karen J. Carlini, CASAC

Coalition for
Community Services (NY)

Natalie Costa

Producer,
Behind the Orange Curtain
(Documentary)

Bradley DeHaven

Author-Activist,
www.RxDrugAddict.com

Michele Gleason

Advisory Committee Member,
Connect the Pieces

Ada Giudice-Tompson

Vice President,
Advocates for the Reform
of Prescription Opioids, Inc.
(ARPO)

Brittany Horigan

Director of Administration,
New Roads Treatment Centers

Avi Israel

President,
Save the Michaels of the World

Peter W. Jackson

President,
Advocates for the Reform
of Prescription Opioids, Inc.
(ARPO)

Andrew Kolodny, MD

President,
Physicians for Responsible
Opioid Prescribing (PROP)

Sandra Kresser

Treasurer,
Advocates for the Reform
of Prescription Opioids, Inc.
(ARPO)

Teri Kroll

Coordinator, PUSH/LICADD

Jan McGrory

Founder,
Lower Cape Community
Addiction Network

Joanne Peterson

Founder and Executive Director,
Learn to Cope

April J. Rovero

Founder/CEO,
National Coalition Against
Prescription Drug Abuse
(NCAPDA)

Sherrie Rubin

Founder and Director,
The Hope2gether Foundation

Staff: **Scarlet Gleeson**

February 26, 2014

Margaret A. Hamburg, M.D.
Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

RE: New Drug Application NDA 202880, Zohydro ER

Dear Dr. Hamburg,

We are writing to echo concerns raised in letters written by Members of the United States Congress and by State Attorneys General regarding the Food and Drug Administration's (FDA) approval of Zohydro, a high-dose, single-entity hydrocodone formulation. We join them in asking you to adopt the recommendation of the FDA-appointed scientific advisory panel, which voted 11-2 against approval of Zohydro.

On behalf of consumer safety organizations, health care agencies, addiction treatment providers, community-based drug and alcohol prevention programs, professional organizations, and other groups on the front-line of our nation's opioid addiction epidemic, we ask you to put the public's health ahead of industry interests. In the midst of a severe drug addiction epidemic fueled by overprescribing of opioids, the very last thing the country needs is a new, dangerous, high-dose opioid.

If your decision to approve Zohydro was based on adherence to existing FDA policies, then surely those policies require urgent revision. FDA must take into account recent history. After the release of similar high-dose opioid analgesics, thousands of lives were lost from overdose and hundreds of thousands of medical and non-medical users became addicted. We implore you to take these painful lessons into account.

Over the past 15 years, prescriptions for opioids have skyrocketed. The United States, with about 5% of the world's population, is now consuming more than 84% of the world's entire oxycodone supply and more than 99% of the hydrocodone supply.¹ According to the United States Centers for Disease Control (CDC), the sharp increase in opioid prescribing has led to parallel increases in opioid addiction and overdose deaths. Since 1999, overdose deaths have skyrocketed, especially among middle-aged individuals prescribed opioids for chronic pain. Opioid analgesic overdose deaths have increased by 415% in women and 265% in men.²


Zohydro's maker has claimed that it is safer than existing hydrocodone products because it does not contain acetaminophen. Zohydro is not safer. The highest available dosage of Zohydro will contain 5 to 10 times more hydrocodone than Vicodin or Lortab. Someone unaccustomed to taking opioids could suffer a fatal overdose from just two capsules. A single capsule could be fatal if swallowed by a child. For patients unable to tolerate acetaminophen, many opioid formulations made without acetaminophen are already available. There is no need for another high-dose, single-entity opioid.

Too many people have already become addicted to similar opioid medications and too many lives have been lost. We urge you to exercise your authority and responsibility to protect the public's health by keeping Zohydro off the market.

Sincerely,

¹ United States hydrocodone and oxycodone consumption statistics as reported by the International Narcotics Control Board in 2012.

² CDC. Vital signs: Overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. MMWR 2013; 62:537-542



G. Caleb Alexander, MD, FACP
Co-Director, Johns Hopkins Center for Drug Safety and Effectiveness
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD



Samuel A. Ball, PhD
President and CEO
CASAColumbia®
New York, NY



Carol Bowman, MD
Director of Pain Recovery
Father Martin's Ashley
Havre de Grace, MD



Daniel A. Busch, MD
Northwestern University, Feinberg School of Medicine
Founder, StopDrugDeath.com
Evanston, IL



Michael A. Carome, MD
Director
Public Citizen's Health Research Group
Washington, DC



Pamela Clark
Director
Transforming Youth Recovery
Reno, NV



Janet Colbert
CEO
STOPPNOW
Broward County, FL



Ann D. Constantino
President and CEO
Horizon Health Services
Buffalo, NY




Kelly M. Corredor
President and CEO
The Skeeterhawk Experiment
Jacksonville, FL



Bradley DeHaven
Founder
RxDrugAddict.com
Sacramento, CA



Kelly Densmore
Co-Founder
Mothers With a Purpose
Pleasanton, CA



Michael S. Early
Executive VP & Chief Clinical Officer
Caron Treatment Centers
Wernersville, PA




Richard L. Falzone, MD, LLC
Instructor of Psychiatry, Harvard Medical School
Founder, RAD Wellness Program
Melrose, MA



Maryanne Frangules
Executive Director
Massachusetts Organization for Addiction Recovery (MOAR)
Boston, MA



Stuart Gitlow, MD, MBA, MPH, FAPA
President
American Society of Addiction Medicine (ASAM)
Chevy Chase, MD



Amy Graves
President
Get Prescription Drugs off the Street
Canada

David Healy, MD, FRCP
Co-Founder
RxISK.org/Data Based Medicine
Toronto, Canada

Avi Israel
President
Save the Michaels of the World
Buffalo, NY

Peter W. Jackson
President
Advocates for the Reform of Prescription Opioids, Inc. (ARPO)
Chicago, IL

Andrew Kolodny, MD
President
Physicians for Responsible Opioid Prescribing (PROP)
New York, NY

Teri Kroll
Coordinator
People United to Stop Heroin on Long Island (PUSH-LI)
Mineola, NY

Danesh Mazloomdoost, MD
Founder
Pain Management Medicine
Lexington, KY

Rebecca McGoldrick
Executive Director
Protect Families First
Providence, RI

Janis McGrory
Founder
Lower Cape Community Anti-Drug Network
Cape Cod, MA

Katherine McHugh
Chair
Freedom from Addiction Network (FAN)
Hyannis, MA

Michele McTiernan-Gleason
Director of Recovery Wellness
Connect the Pieces to Prevent Prescription Drug Abuse
Boise, ID

Howard Meitner
President and CEO
Phoenix House
New York, NY

/s/
Karen H. Perry
Executive Director
NOPE Task Force
West Palm Beach, FL

Joanne Peterson
Founder and Executive Director
Learn2Cope
Boston, MA

Mel Pohl, MD
Medical Director
Las Vegas Recovery Center
Las Vegas, NV

Raghu Ram, MD
Vice President and Chief Medical Officer
HealthNow New York Inc., d/b/a
BlueCross BlueShield of Western New York (Buffalo) and
BlueShield of Northeastern New York (Albany)

April J. Rovero
President
National Coalition Against Prescription Drug Abuse (NCAPDA)
San Ramon, CA

Jeffrey L. Reynolds, Ph.D., CEAP, SAP
Executive Director
Long Island Council on Alcoholism & Drug Dependence (LICADD)
Mineola, NY

Sherrie Rubin
Director
The Hope2gether Foundation
San Diego, CA

Judy Rummler
President
Steve Rummler Hope Foundation
Minneapolis, MN

Susan Salomone
Founder
Drug Crisis in our Backyard
Mahopac, NY

Marvin D. Seppala, MD
Chief Medical Officer
Hazelden Foundation
Center City, MN

Dan Smoot
President and CEO
Operation UNITE
London, KY

Raymond V. Tamasi
President and CEO
Gosnold on Cape Cod
Falmouth, MA

Ken Thompson, MD
Trusted Servant
Like Minded Docs
Strasburg, PA

Dirk Wales
Director
Get Unhooked
Santa Fe, NM

Kim Witczak
Founder
WoodyMatters.com
Minneapolis, MN